CCMB study points to new way of tackling fungal infections


CCMB’s Sriram Varahan (at the left) with his research team found new way to tackle fungal infections

CCMB’s Sriram Varahan (at the left) with his research team found new way to tackle fungal infections
| Photo Credit: BY ARRANGEMENT

Scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, have identified a promising new strategy to combat fungal infections by preventing disease-causing fungi from becoming invasive, rather than killing them outright.

A drawback of current antifunal drugs

Most current antifungal drugs work by destroying fungal cells. However, fungi can gradually develop resistance to these medicines, making infections increasingly difficult to treat. A team led by Sriram Varahan at CCMB studied ‘Candida albicans’, a fungus commonly found on human skin and in the body. While generally harmless, it can cause serious infections when it enters the bloodstream or internal organs.

The researchers focused on ‘morphogenesis’, in which the fungus changes from a round-cell form into long, filament-like structures, a transformation allowing the pathogen to evade the body’s immune defences and spread more effectively within tissues.

What did CCMB scientists target?

Earlier studies had shown that glycolysis, the process through which cells metabolise sugar, plays a key role in controlling this shape change. Building on these findings, the team screened a library of small molecules that target glycolysis and identified two compounds capable of blocking the transformation.

Although the fungus continued to grow, it remained in its harmless rounded form suggesting that the compounds could serve as “anti-infective” agents that reduce the fungus’ ability to cause disease without necessarily eliminating it.

The study also identified pyruvate kinase, an enzyme involved in sugar metabolism, as a crucial regulator of fungal morphogenesis. Researchers further found that one of the compounds reduced biofilm formation, a protective layer that helps fungi resist treatment. The compound also increased the effectiveness of widely used antifungal drugs such as fluconazole and amphotericin B.

In a mouse model of systemic Candida infection, treatment with the lead compound significantly improved survival rates, highlighting its potential for future therapeutic development. “Our findings suggest that fungal disease-associated behaviour can be targeted without necessarily stopping fungal growth,” said Dhrumi Shah, first author of the study. “We need further studies to evaluate the compounds effectiveness and safety but by blocking the fungus from becoming invasive, they could complement existing treatments,” said Sriram Varahan.

The findings, published in ACS Infectious Diseases, emerged from a collaboration between CSIR-CCMB and the BRIC-Translational Health Science and Technology Institute, said a press release on Tuesday.

  • Related Posts

    China’s LineShine retains top spot on list of world’s most powerful supercomputers

    Image used for representational purposes only. | Photo Credit: Getty Images/iStockphoto China’s LineShine supercomputer has retained its top spot in the list of the world’s most powerful supercomputers, whose latest…

    Continue reading
    NASA Voyager 1 probe believed to have reached ‘light-day’ milestone

    An artist’s concept depicts a NASA Voyager spacecraft travelling through interstellar space. File | Photo Credit: Reuters NASA’s Voyager 1 probe is believed to have now ​hit a distance milestone…

    Continue reading